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Abstract 
Significance: During the last decades, thiosemicarbazones have been clinically developed 
for a variety of diseases including tuberculosis, viral infections, malaria and cancer. With 
regard to malignant diseases, the class of α-N-heterocyclic thiosemicarbazones, and here 
especially Triapine, was intensively developed in multiple clinical phase I/II trials.  
Recent Advances: Very recently two new derivatives, namely COTI-2 and DpC have 
entered phase I evaluation. Based on the strong metal-chelating/metal-interacting 
properties of thiosemicarbazones, interference with the cellular iron (and copper) 
homeostasis is assumed to play an important role in their biological activity. 
Critical Issues: In this review, we summarize and analyze the data on the interaction of (α-
N-heterocyclic) thiosemicarbazones with iron, with the special aim to bridge the current 
knowledge on their mode of action from chemistry to (cell) biology. In addition, we 
highlight the difference to classical iron(III) chelators such as desferrioxamine (DFO) which 
are used for the treatment of iron overload.  
Future Directions: We want to emphasize that thiosemicarbazones are not solely 
removing iron from the cells/organism. In contrast, they should be considered as iron-
interacting drugs influencing diverse biological pathways with a complex and multi-
facetted mode of action. Consequently, in addition to the discussion of physicochemical 
properties (e.g. complex stability, redox activity), this review contains an overview on the 
diversity of cellular thiosemicarbazone targets and drug resistance mechanisms.  
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Introduction  
During the last decades, thiosemicarbazones have been clinically developed for a variety of 
diseases including tuberculosis, viral infections, malaria and cancer. The first clinically 
approved drug of this compound class (introduced in the late 1940s) was p-
acetamidobenzaldehyde thiosemicarbazone (Thioacetazone, Figure 1), which is still used 
for the treatment of multidrug-resistant tuberculosis (40,41,140). The second clinically 
investigated thiosemicarbazone (commercialized in the 1960s) was N-methylisatin 
thiosemicarbazone (Methisazone, Figure 1), an agent developed against smallpox, which, 
however, due to the development of the smallpox vaccination, is not administered 
anymore (129). The clinical anticancer research mainly focused on α-N-heterocyclic 
thiosemicarbazones. As these compounds are very potent chelators for metal ions 
including iron, they were originally developed with the aim to target the enhanced 
demand of cancer cells for iron (181). Already in 1956, the first derivative, 2-formylpyridine 
thiosemicarbazone (FTSC, Figure 2) was reported to show activity against leukemia in mice 
(154). After extensive structure-activity studies the most promising compound, 5-hydroxyl-
2-formylpyridine thiosemicarbazone (5-HP, Figure 1), was tested in clinical phase I trials 
and was shown to possess anticancer activity in leukemia patients (37,103). Unfortunately, 
these tests also revealed severe side effects (mainly gastrointestinal toxicity) and fast 
inactivation by glucoronidation leading to the withdrawal of the compound (37,103). 
Further optimization led to the development of 3-aminopyridine-2-carboxaldehyde 
thiosemicarbazone (Triapine, 3-AP, Figure 1), a compound which has meanwhile been 
tested in more than 30 clinical phase I and II trials (4,47,56,91,132). Similarly to the results 
obtained with 5-HP, Triapine showed promising activity against hematologic diseases, 
while solid cancers proved unresponsive. The reasons for this inefficacy of Triapine 
monotherapy against solid tumors are still not fully understood. Probable explanations 
(discussed in more detail below) include inappropriate drug delivery due to the very short 
plasma half-life (47,132,143), fast metabolism/excretion (142)  and/or rapid development 
of drug resistance (127). Despite these drawbacks, thiosemicarbazones have remained the 
focus of interest. Thus, several recent phase I studies have been performed testing the 
safety of Triapine in combination therapy (e.g. with cisplatin (106,109), gemcitabine (91), 
cytarabine (137), doxorubicin (163), irinotecan (26) or radiation (109)). In addition, there 
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are currently two new α-N-heterocyclic thiosemicarbazones undergoing clinical evaluation. 
In December 2015, COTI-2 (developed by Critical Outcome Technologies Inc., Figure 1) 
(159) entered a clinical phase I trial for treatment of advanced or recurrent gynecologic 
malignancies (NCT02433626). According to the information provided by the company, 
COTI-2 displays strong anticancer activity in the nanomolar range, especially in p53-mutant 
cell lines, as this thiosemicarbazone (comparable to some other thiosemicarbazones 
discovered by the NCI (78)) restores the wild-type function of the p53 protein (see below). 
The second currently tested thiosemicarbazone is di-2-pyridylketone 4-cyclohexyl-4-
methyl-3-thiosemicarbazone (DpC, developed by Oncochel Therapeutics, Figure 1) (61), 
which has been under clinical phase I evaluation since January 2016 (NCT02688101) in 
order to assess its pharmacokinetic characteristics and the maximum tolerated dose in 
patients with a range of advanced and resistant tumors.  
Based on these promising recent developments, the elucidation of the mechanisms 
underlying the (biological) activity of the different anticancer thiosemicarbazones remains 
of high interest. In this review we summarize and analyze the data on the interaction of (α-
N-heterocyclic) thiosemicarbazones with iron, with the special aim to connect the chemical 
properties with the current knowledge on (cell) biological modes of action. In contrast to 
several drugs such as desferrioxamine (DFO), which are used for the treatment of iron 
overload and selectively chelate iron(III), α-N-heterocyclic thiosemicarbazones usually 
form stable complexes with both iron(II) and iron(III) and therefore are able to redox cycle 
between these two oxidation states under physiological conditions. Throughout this 
review we emphasize that thiosemicarbazones are not “simple” iron chelators (solely 
removing iron from the circulation or the cells), but in contrast have to be considered 
rather as iron-interacting drugs, which affect diverse biological pathways with a complex 
and multi-facetted mode of action. Based on the broad metal affinity, at least for some 
thiosemicarbazone derivatives, further biologically relevant metal ions (especially copper 
and zinc) have been associated with their mechanism(s) of action. However, due to the 
restriction in the length, this review does not comprehensively cover these additional 
metal ions. Furthermore, it is beyond the scope of this review to give an overview on 
human iron homeostasis, especially as there are several excellent reviews in literature 
covering this field (24,54,87).  
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Important physico-chemical parameters for the metal-binding ability of α-N-heterocyclic 
thiosemicarbazones  
Given the importance of metal binding in the biological activity of α-N-heterocyclic 
thiosemicarbazones, the chemical characteristics influencing their metal binding have 
been intensively investigated over the last few decades. These studies revealed that a 
profound knowledge of the solution stability, stoichiometry and redox properties of the 
metal complexes (especially iron(II)/(III)) under physiological conditions as well as 
lipophilicity or pKa of the ligands is mandatory for the understanding of structure-activity 
relationships of this compound class. In case of thiosemicarbazone iron complexes, the 
possibility to readily switch in an one-electron oxidation-reduction reaction between the 
ferrous form, Fe(II), and the ferric form, Fe(III) is of high importance to understand the 
biological effects. Consequently, the type of donor atoms which coordinate to the iron ions 
strongly influences not only the overall stability of the complexes but also determines if or 
in which electrochemical window redox cycling between the two iron oxidation states is 
possible.  
In general, thiosemicarbazones coordinate to metal ions by a bidentate binding mode via a 
neutral nitrogen/sulfur (N,S) or anionic (N,S‒) donor set. However, metal complexes with 
much higher stability can be formed when an additional coordinating functionality is 
present in the molecule as in the case of α-N-heterocyclic thiosemicarbazones (usually 
containing a pyridyl moiety) resulting in a (N,N,S) donor set (Figure 2, coordinating atoms 
are indicated).  
Unfortunately, solution stability constants have been published only for a few α-N-
heterocyclic thiosemicarbazone iron complexes, making the comparison of the different 
analogues difficult. So far, comparable stability data are available only for various 
derivatives of 2-formylpyridine thiosemicarbazone (FTSC) including Triapine (8,44) and di-
2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) (52) with (N,N,S) donor 
atoms as well as salicylaldehyde thiosemicarbazone (STSC) containing an (O,N,S) donor set 
(43,128) (Figure 2). In the following sections we will summarize the available data and 
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explain correlations between complex stability in solution, proton dissociation constants 
and redox properties.  
 
pKa values of metal-free α-N-heterocyclic thiosemicarbazones 
As a first parameter to compare different thiosemicarbazone complexes, the proton 
dissociation behavior of the ligands is of interest to understand the complex stability and 
the composition of the formed species. In general, simple α-N-pyridyl thiosemicarbazones 
(such as FTSC) possess two dissociable protons. Here, the pK1 (~3‒4) can be attributed to 
deprotonation of the pyridinium unit and pK2 (~10.5‒11.5) to the deprotonation of the 
hydrazinic N-H group of the thiosemicarbazide moiety (Figure 3). In case of pK2, the 
resulting negative charge is mainly localized on the S atom via the thione–thiol tautomeric 
equilibrium (Figure 3) and is influenced by the presence of different substituents. Thus, for 
example, N-terminal dimethylation significantly decreases the pK2 values (43). Based on 
the pKa values, at physiological pH all these α-N-pyridyl thiosemicarbazones are charged 
neutral (denoted as “HL form”) enabling an easier passage across the cell membrane.  
 
Characteristics of iron(II/III) thiosemicarbazone complexes 
Due to their tridentate nature, α-N-pyridyl thiosemicarbazones form octahedral 
mono- and bis-ligand complexes with iron(II/III) ions resulting in species such as Fe(HL), 
FeL, FeL(HL), or FeL2 (where L is the completely deprotonated form of the ligand; Figure 3). 
In the protonated complexes Fe(HL) and FeL(HL), which are formed under acidic 
conditions, the HL ligand coordinates via the (Npyridyl,N,S) donor set with the proton 
attributed to the non-coordinating hydrazinic-N atom (44). In contrast, at neutral and basic 
pH values FeL and FeL2 complexes are formed, with anionic ligand(s) coordinating via 
(Npyridyl,N,S‒) together with deprotonation of the hydrazinic nitrogen. This was also 
confirmed by X-ray diffraction measurements for numerous iron(III) species (99,102,173).  
On the basis of the reported solution equilibrium data for the iron complexes of α-
N-pyridyl thiosemicarbazones (including Triapine and Dp44mT, Table 1), it can be 
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concluded that at slightly acidic and physiological pH the FeL2-type complexes 
predominate (44,52).  
 
However, due to differences in the number of dissociable protons and the basicity of the 
ligands, the log β values (a cumulative formation constant for the complexes) of the iron 
complexes shown in Table 1 cannot be directly compared. Still, log β values clearly show 
that the differences between the constants of the iron(III) and iron(II) complexes strongly 
depend on the type of ligand. For example, stability constants of the iron(II) and iron(III) 
complexes of the clinically approved iron chelator DFO (Figure 2) differ by ~20 orders of 
magnitude. In contrast, among the group of α-N-pyridyl thiosemicarbazones the difference 
is in general much smaller encompassing only 2–3 orders of magnitude (Table 1). The 
impact of the different donor atom sets in the thiosemicarbazone structure (N,N,S‒ vs. O‒
,N,S‒) can be demonstrated by comparing the stability of iron(II/III) complexes formed by 
FTSC and STSC (Figure 4). Thus, in a hypothetical metal/FTSC/STSC ternary system, the 
STSC ligands with the (O,N,S,) donor set have a much higher affinity for Fe(III) ions, 
whereas the (N,N,S) donor set of FTSC prefers iron(II) ions. This preference corresponds to 
the different hard-soft character of metal ions and the donor atoms (87,89). The 
underlying theory behind the so-called HSAB (hard and soft acid and bases) concept (141) 
is that transition metals (“Lewis acids”) as well as donor atoms of the potential ligands 
(“Lewis bases”) can be classified into soft (low charge/large ionic radius), borderline, and 
hard (high charge/small ionic radius). According to this concept, soft acids react more 
efficiently and form stronger bonds with soft bases, whereas hard acids form stronger 
bonds with hard bases. Thus, the hard Lewis acid Fe(III) will be preferentially coordinated 
by the STSC ligand (O,N,S) possessing the hard oxygen donor, while due to the softer 
(N,N,S) donor set, α-N-pyridyl thiosemicarbazones are unambiguously more efficient 
chelators of iron(II). 
Beside the type of the coordinating donor atoms, also substituents on the 
thiosemicarbazone backbone can distinctly modify the stability of the respective metal 
complexes. For example, the iron(II)-binding ability of FTSC is weaker compared to that of 
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Triapine, which in turn is weaker than that of the N-terminally dimethylated 2-
formylpyridine thiosemicarbazone (PTSC) (44). Notably, the iron(II)-binding ability is in 
strong correlation with the anticancer activity of the compounds, with PTSC being the 
compound with the highest and FTSC the lowest cytotoxicity (in the nM and µM range, 
respectively) (102). This correlation also fits to the much lower stability of the STSC iron(II) 
complex and its low cytotoxic activity (45,117,148). Overall, these data highlight the 
importance of the iron(II)-binding affinity of thiosemicarbazones in the optimization of 
their anticancer effects. However, it has to be considered that the analytical data for 
determination of the complex stability are usually measured in a concentration range of 
~10 µM to 1 mM. Consequently, binding affinities in the low µM to nM range are based on 
extrapolations, which make a profound estimation of the interaction of 
thiosemicarbazones with iron ions especially in the low nM range very difficult. This is 
especially of relevance in case of several highly active derivatives such as PTSC (42), DpC 
(116), and Dp44mT (14), in which N-terminal dimethylation (or more general dialkylation) 
results in a dramatically increased cytotoxic activity as compared to derivatives with an 
unsubstituted terminal NH2 moiety (e.g. FTSC and Triapine). In case of these 
thiosemicarbazones, we can only speculate, whether they are indeed still able to bind 
iron(II)/(III) ions at their nanomolar IC50 concentrations. Noteworthy, detailed structure-
activity relationship studies revealed that this increased activity only occurs if no NH2 or 
even NH group (with the exception of the hydrazinic NH) is present in the molecule 
(101,102). Consequently, the terminally dimethylated derivative of Triapine has a cytotoxic 
activity comparable to Triapine itself (102) and only dimethylation of both amino groups 
results in a nanomolar activity (101). However, the underlying mechanisms and the role of 
iron complexation in this highly increased cytotoxic activity are widely unknown. There are 
some indications that thiosemicarbazones being active in the nanomolar concentration 
range are characterized by an additional mode of action (and also induce different 
resistance patterns), which might involve interaction with copper, which is discussed in 
more detail below (53,83,101). 
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Solution stability and redox potential 
The ratio between the cumulative stability constants of the iron(II) and iron(III) 
complexes is strongly connected to the redox potential. The reason is that the formal 
redox potential (ε’) of the Fe(III)/Fe(II) redox couple is determined by the ratio of the 
cumulative stability constants of the iron(III) and the iron(II) complexes according to the 
general Eq.1.(172) 
’Fe(III)complex/Fe(II)complex ‒ ’Fe(III)aqua/Fe(II)aqua = ‒59.15×log(Fe(III)complex / Fe(II)complex)   (Eq.1). 
Therefore, an increasing formal potential obtained at pH 7.4 represents an increasing 
affinity of the ligand towards iron(II) compared to iron(III) (Table 2). As a consequence, e.g. 
the iron complexes formed with the aromatic nitrogen donor atom-containing bidentate 
ligand 1,10-phenantholine (Figure 2) are characterized by a very high formal potential of 
the iron complex (+1140 mV vs. normal hydrogen electrode (NHE) (113)) and, therefore, 
the iron(III) complex shows low stability in aqueous solution (122). In contrast, the iron 
complexes of chelators applied for the treatment of iron overload such as DFO, 
deferiprone and deferasirox (Figure 2) are characterized by very low redox potentials 
(Table 2) and, consequently, very high iron(III)-binding abilities (reflected by high pM 
values, which is the negative logarithm of the equilibrium concentrations of the unbound 
metal ion). For example, in case of DFO, which has a formal redox potential of –482 mV vs. 
NHE (172), the iron(II) complex has much lower stability compared to the respective 
iron(III) complex (46,69). Under anaerobic conditions (at physiological pH) DFO is even able 
to oxidize iron(II) to iron(III) (46). The reason for this behavior is that these agents mainly 
contain hard oxygen donor atoms, which are ideal for iron(III) binding (87,89). This feature 
results in a very high binding efficacy and provides the enormous selectivity of these 
ligands for iron(III), not only in comparison to iron(II) but also to other essential bivalent 
metal ions like zinc(II) and copper(II). In addition, due to the low ε’ values, iron complexes 
of these chelators do not redox cycle under physiological conditions (76) preventing 
generation of reactive oxygen species (ROS) via  Fenton-type reactions.  
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In contrast to the (mainly oxygen-containing) chelators developed for the treatment of 
iron overload, anticancer α-N-pyridyl thiosemicarbazones such as Triapine, DpC or Dp44mT 
coordinate metals via their (Npyridyl,N,S‒) donor set. As a result of this binding mode, the 
redox potentials of their iron complexes are significantly higher (in the range of ‒170 mV 
to +170 mV vs. NHE) (44,155) compared to DFO, deferiprone or deferasirox (–482 mV to –
620 mV vs. NHE; see Table 2). Consequently, α-N-pyridyl thiosemicarbazones show a 
considerably high affinity towards both iron(II) as well as iron(III) ions. This property 
enables the iron thiosemicarbazone complexes to redox cycle between the two oxidations 
states, as these redox potentials are accessible to intracellular oxidants and reductants 
(66,87,155). Redox cycling is considered as an important factor in the antiproliferative 
activity of these compounds (although the correlation between the redox potential and 
cytotoxicity is not as evident as the relation between stability and cytotoxicity). In line with 
the relevance of redox cycling for anticancer thiosemicarbazones, iron(III)-specific 
chelators such as DFO are generally not efficient antitumor agents and can be safely used 
to treat iron overload (23,116,197). This already indicates that “iron depletion” in itself is 
not sufficient to explain the anticancer activity of thiosemicarbazones.  
Interaction of thiosemicarbazones with the body iron  
 
Based on the above-described features of thiosemicarbazones, there is no doubt that 
interaction with iron plays an important role in the biological activity of Triapine as well as 
many other α-N-heterocyclic derivatives. In addition to cell culture studies (discussed in 
more detail below), which investigated the role of iron and other metal ions in the activity 
of thiosemicarbazones on a cellular level, there are reports from clinical trials on the 
interaction of thiosemicarbazones with iron metabolism. For example, in case of 5-HP, 
excretion of the green-colored iron complex was observed in the urine of treated patients 
within a few hours after drug administration (103). In contrast, in Triapine-treated patients 
(or animals) (47,132,143)) no coloring of urine but methemoglobin formation (oxidation of 
iron(II) to iron(III) in hemoglobin) was observed which is a prominent indication for its 
interaction with body iron. This type of adverse effect, observed in ~23% of Triapine-
D
ow
nl
oa
de
d 
by
 K
in
gs
 C
ol
le
ge
 L
on
do
n-
jou
rna
l S
ect
ion
 fr
om
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 01
/16
/18
. F
or 
pe
rso
na
l u
se 
on
ly.
 
Page 12 of 63 
 
 
 
12 
An
tio
xid
an
ts
 a
nd
 R
ed
ox
 S
ig
na
lin
g 
An
tic
an
ce
r t
hi
os
em
ica
rb
az
on
es
: c
he
m
ica
l p
ro
pe
rt
ie
s, 
in
te
ra
ct
io
n 
w
ith
 ir
on
 m
et
ab
ol
ism
, a
nd
 re
sis
ta
nc
e 
de
ve
lo
pm
en
t (
DO
I: 
10
.1
08
9/
ar
s.2
01
7.
74
87
) 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
treated patients (94,107), was also reported for several preclinically developed α-N-
heterocyclic thiosemicarbazones such as Dp44mT (150) (in this study methemoglobin 
formation was analyzed in mice as well as in isolated human red blood cells) (Table 3). 
With regard to the underlying mechanism, the iron(III) complex of Triapine is believed to 
oxidize the iron(II) in the hemoglobin molecule by direct electron transfer (183). In line 
with the supposed role of a redox reaction in the thiosemicarbazone-induced 
methemoglobin formation, clinical trials with Triapine additionally indicated that patients 
with a glucose-6-phosphate deficiency suffered from enhanced methemoglobin levels and 
even hemolysis after treatment (199). Since glucose-6-phosphate is important in the 
protection of red blood cells from oxidative stress (184), this supports the assumption that 
Triapine treatment interferes with redox homeostasis. Methemoglobin formation seems 
to be strongly dependent on the interaction of the terminally unsubstituted NH2 groups of 
the thiosemicarbazone iron complexes with the carboxylic acid groups of the porphyrins of 
hemoglobin (Figure 5) (11,12,143). Consequently, novel α-N-heterocyclic 
thiosemicarbazones such as DpC (and probably also COTI-2) carrying a bulky substituent at 
this position are far less potent methemoglobin inducers than their predecessors (12).  
Besides methemoglobin formation, also other iron-associated biological parameters were 
affected by Triapine treatment. Wadler et al. (186) described that after 96 h of continuous 
Triapine infusion serum iron and ferritin levels transiently increased by 104% and 77%, 
respectively. Remarkably, the total iron-binding capacity of the blood remained unchanged 
in these patients, indicating that there was no net loss of iron from the body. 
Consequently, the authors concluded that (in contrast to 5-HP or the traditional iron(III) 
chelators (103)) Triapine-bound iron might be recovered during its hepatic metabolism and 
the increased delivery of iron to the liver could induce production of ferritin explaining the 
elevated serum levels of this protein. Interestingly, despite these distinct impacts on 
several iron-associated clinical parameters, all attempts to detect the formation of an iron-
Triapine complex in vivo or even in cell culture have failed so far (95,96,143).  
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Cancer-associated cellular targets of thiosemicarbazones 
 
1) Ribonucleotide reductase 
The iron-containing enzyme ribonucleotide reductase (RR) is most probably the best 
described target of anticancer α-N-heterocyclic thiosemicarbazones (Table 3). This 
metalloenzyme catalyzes the conversion of ribonucleoside diphosphates (NTPs) to 
deoxyribonucleoside diphosphates (dNTPs). Therefore, it is crucial for DNA synthesis as 
well as DNA damage repair and is frequently overexpressed in cancer cells making it an 
attractive target for treatment. The RR is a tetrameric protein composed of two large 
subunits (hRRM1) that are important for substrate binding, and two small iron-containing 
R2 subunits being responsible for its enzymatic function (5,25). Two different R2 subtypes 
have been described: i) the hRRM2 subunit, which is a cell cycle-dependent protein, 
strongly upregulated at the beginning of the S-phase and actively degraded via 
ubiquitination during the G2 phase of the cell cycle (60); ii) p53R2 (also called hRRM2B), a 
subunit which is expressed at lower levels than hRRM2 but is not degraded during mitosis 
(138) and therefore its levels remain constant during the cell cycle. In addition, reports 
suggest that expression of this subunit can be induced in a p53-dependent manner. 
Consequently, it is assumed that the so formed protein is involved in several cellular 
functions including DNA repair, cell cycle arrest and mitochondrial homeostasis (5,25).  
Inhibition of the tyrosyl radical in the active center of the hRRM2/p53R2 subunit was 
demonstrated for several thiosemicarbazones (including Triapine and Dp44mT) as well as 
diverse iron chelators (like phen and DFO) mainly in cell-free systems 
(6,59,74,99,167,178,198,202). The best-investigated thiosemicarbazones with regard to RR 
inhibition are Triapine and its closest analogs, for which detailed in vitro studies were 
performed during the last decades. In addition, a phase I trial with Triapine demonstrated 
the depletion of dATP and dGTP pools together with a decrease of DNA synthesis in 
circulating leukemia cells (56).  
With regard to the mechanism, it was initially assumed that Triapine inhibits the hRRM2 
subunit through iron chelation, either from the active site of the protein or from the 
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cellular labile iron pool (5). However, this theory was questioned by several observations 
indicating that in fact Triapine seems to be a surprisingly inefficient iron chelator in cell 
culture. For example, it was shown that, in contrast to DFO, Triapine had a relatively weak 
effect on cellular transferrin receptor levels of SK-N-MC cells (23) perhaps due to the 
weaker iron(III)-binding ability compared to DFO. Also, electron paramagnetic resonance 
(EPR) spectroscopic analyses of Triapine-treated K562 cells (5 or 500 µM) showed no 
change in the size of the g = 4.3 signals (typical for intracellular iron-chelate complexes) 
after 0.5, 3 and 12 h of treatment, which would be indicative for depletion of the 
intracellular iron(III) pools (6). The same authors showed that in the presence of Triapine 
the loss of iron bound inside the RR molecule was five times lower than the destruction of 
the tyrosyl radical (5,6) and subsequent investigations of Triapine-treated COS-1 cells 
indicated iron-loaded hRRM2 (with a quenched tyrosyl radical) as the main remaining 
protein species, arguing against iron chelation from the enzyme. Moreover, in these COS-1 
cells Triapine did not change the aconitase activity (6). This is of interest, as this protein 
contains an essential [4Fe4S] cluster, which is ROS-sensitive and could be influenced by 
depletion of the labile iron pool (6). Consequently, the authors of this study concluded that 
Triapine is not only ineffective in sequestering iron inside the cell, but also that it is unlikely 
to be involved in disruption of biosynthesis or repair of metallo-cofactor-requiring proteins 
(6).  
Based on the repeated observations, that in cell-free systems metal-bound Triapine 
(particularly the iron(II) complex) possesses a dramatically increased ability to inhibit 
hRRM2 compared to the metal-free ligand (6,146,167,202), several authors speculated 
that the active species responsible for cell killing is in fact the iron complex of Triapine. In 
more detail, it was assumed that upon intracellular formation of the redox-active iron 
complex, ROS are generated, which are ultimately responsible for RR inhibition (167). 
Interestingly, the pronounced activity of Triapine and close derivatives against hRRM2 in 
the presence of iron was not observed in cell-free systems of p53R2, and co-incubation 
with iron had even protective effects against the inhibition of this enzyme (202). 
Furthermore, there are several reports suggesting that at biologically active concentrations 
no substantial ROS generation was detected after treatment with metal-free Triapine or 
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other close derivatives (100,115,134). In line with these observations, recent studies have 
revealed no oxidation of hRRM2 residues or the accumulation of oxidized cellular proteins 
(neither in cell-free nor in cell culture experiments) after Triapine treatment, suggesting 
that global ROS generation might not be mandatory for RR inhibition by Triapine (5,6). 
Notably, as already mentioned before, despite several attempts (96,143) intracellular 
formation of a Triapine-iron complex has not been directly demonstrated either in vitro or 
in vivo. Taken together, while the importance and necessity of iron-binding in the 
anticancer activity of thiosemicarbazones is proven without doubt (derivatives and 
metabolites lacking a metal-binding domain are completely inactive (142,147,200)), the 
exact mode of action remains elusive. 
Consequently, several alternative theories have been published to offer an explanation 
how Triapine could inhibit the RR without the direct chelation of the enzyme-bound iron or 
the production of ROS. On the one hand, it was suggested (comparably to the interaction 
with hemoglobin in the methemoglobin formation) that the iron(II) complex of Triapine 
could act as reductant, directly reducing the tyrosyl radical of the hRRM2 subunit (6). This 
is of interest as direct binding of Triapine to hRRM2 and p53R2 was shown by radioactive 
labelling (202), which was only slightly affected by addition of iron. In line with these 
experimental data, docking studies of mouse RR revealed a possible Triapine-binding site 
with the pyridine ring of the thiosemicarbazone located in the pocket of the four amino 
acids Phe237, Phe241, Ser238 and Tyr324 (146). Based on these results, it can be 
hypothesized that, following the binding of (metal-free) Triapine to the enzyme, an iron 
complex is formed locally, using the iron liberated during each catalytic cycle of the RR. 
Another possible mechanism is based on the effect of Triapine on intracellular thiol 
homeostasis. Here, especially the effects on the thioredoxin system seem to be of 
importance, as thioredoxin (Trx) or glutaredoxin are necessary to reactivate the RR enzyme 
after the end of each reaction cycle. In detail, during the conversion cycle of NTPs to dNTPs 
a disulphide bond is formed in the hRRM1 subunit, which has to be reduced before the RR 
can enter a new enzymatic cycle (60,166). Some reports indicate that Triapine as well as 
Dp44mT inhibit thioredoxin reductase (TrxR1) (134,198). However, as these effects were 
observed only at very high concentrations (>50-fold above the IC50 values (133)), it remains 
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unclear whether this is of biological relevance. Interestingly, murine L1210 leukemia cells 
selected for resistance against 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone 
(MAIQ) were (besides the overexpression of several efflux pumps (29)) also characterized 
by overexpression of protein disulfide isomerases (PDI) (30), which are thiol 
oxidoreductase chaperones from the thioredoxin superfamily (171). 
 
2) Impact of thiosemicarbazones on the cell cycle and other (iron-dependent) 
cellular pathways. 
During the last decades, it has been repeatedly reported that treatment with diverse iron 
chelators leads to cell cycle arrest in G0/G1 or early S-phase (27,71,79,147,151,170). One 
explanation certainly is the above-described inhibition of the RR. However, several other 
proteins involved in DNA replication and repair also require iron as a cofactor and thus 
could be influenced by thiosemicarbazones and other iron-chelating drugs. These proteins 
include for example three DNA polymerases (Pol α, Pol δ and Pol ε), several DNA helicases 
(including Rad3/XPD, Dna2, RTEL1, FANCJ and ChIR1) as well as the DNA primase regulator 
subunit PRIM2 (201). In contrast to RR, these polymerases, helicases and primases contain 
an Fe-S cluster, which is necessary for the formation of active holoproteins (201). 
Interestingly, inhibition of RNA polymerases seems to be very important for the antiviral 
activity of several thiosemicarbazones, indicated by point mutations in the enzymes 
leading to drug-resistant virus variants (20,21,31,149). However, there are only a few 
studies (based on cell-free systems) linking polymerase inhibition to cancer (63) and to our 
knowledge there is so far no indication that inhibition of polymerases also occurs in cancer 
cells after thiosemicarbazone treatment. Likewise, the activity of the [4Fe-4S] cluster-
containing aconitase (201) is not affected by Triapine (6), indicating that, in general, 
human Fe-S cluster proteins are not (heavily) affected by thiosemicarbazone treatment. 
In addition to its direct role in proteins executing DNA synthesis, iron also influences cell 
cycle regulation via cyclins and cyclin-dependent kinases (CDKs) (201). Thus, it has been 
repeatedly reported that treatment with diverse iron chelators such as DFO or L-mimosine 
(an amino acid derivative and predecessor of deferiprone) and also thiosemicarbazones 
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results in the downregulation of cyclin A and D (7,23,27,105,110,136) as well as CDK2/4 
(23,35,36,105) (Table 3). Overall, the mechanisms underlying these effects are not fully 
understood and there might be several explanations. For example, in case of CDK2 it was 
reported that binding of iron ions to the protein occurs only to its phosphorylated form, 
indicating a direct regulation of this protein by the cellular metal homeostasis (9). With 
regard to cyclin A, little is known about the mechanisms explaining how 
thiosemicarbazones could influence the expression levels of this protein. Of interest in this 
context might be a recent report on the downregulation of cyclin A (in addition to cyclin D) 
by rolipram, a PDE4 inhibitor (121), which also strongly protects cells from Triapine 
treatment. In addition, loss of PDE4D was the only genomic alteration found in Triapine-
resistant SW480 cells (126). With regard to its biological function PDE4 is a negative 
regulator of cyclic AMP (cAMP), which in turn is one of the most abundant second 
messengers regulating various physiological processes like cell survival, differentiation, 
proliferation and apoptosis (10). One major downstream target of cAMP is cAMP-
dependent protein kinase (protein kinase A, PKA), which then activates the transcription 
factor cAMP responsive element-binding protein (Creb) (157). Consequently, interaction of 
thiosemicarbazones with this regulatory pathway could also serve as an explanation for 
the observed effects on cyclin A.  
More information is available on the mechanisms linking disturbed cellular iron 
homeostasis to the reduced expression of cyclin D1. For example, DFO and 311 (2-hydroxy-
1-naphthylaldehyde isonicotinoyl hydrazine, a congener of PIH) resulted in active 
degradation of cyclin D1 (136), whereas DpC (and in some cell lines also Dp44mT) 
downregulated the expression of cyclin D1 by inhibition of STAT3 dimerization and 
activation (possibly via inhibition of upstream kinases such as Src and Abl) (119,187). 
Interestingly, the described effects were similar for the metal-free ligands and preformed 
iron complexes. In addition to STAT3, treatment with DFO (110), deferasirox (120), L-
mimosine (27), as well as Dp44mT (110,114,120,187) and DpC (97) downregulated cyclin 
D1 also via N-myc downstream-regulated gene 1 or 2 (NDRG1/2), repeatedly shown in cell 
culture and for some drugs also in mouse models (Table 3). However, NDRG1 also has 
multiple other cellular targets including the TGFβ, the Wnt/β-catenin (114), the 
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FAK/paxillin (188), the NF-κB (192), and the ErbB signaling pathways (98). Consequently, it 
is not surprising that besides inhibition of cell cycle progression, the drug-mediated 
stimulation of NDRG1/2 can be linked to several other effects including reduced 
aggressiveness or metastatic potential, which has been described e.g. for Dp44mT- or DpC-
treated hepatocellular and breast carcinoma cells (114,187). Interestingly, NDRG1 has 
recently also been identified as downstream-target of the above mentioned PKA/CREB 
signaling axis (81). Finally, cyclin D1 is also a well-known target of p21waf, which was 
reported to be stimulated by diverse iron(III) chelators including DFO, deferasirox, 311, but 
also Dp44mT, DpC, and TSC24 (N,N-dimethyl-2-(quinolin-2-
ylmethylene)hydrazinecarbothioamide, a terminally dimethylated analogue of FTSC) 
(7,23,32,97,120). P21waf is a down-stream target of the DNA damage sensor p53 (78). 
Considering, the enhanced DNA damage (indicated for example by phosphorylation of the 
damage marker H2XA) which was observed after treatment with different RR inhibitors 
(including Triapine, Dp44mT) in cell culture (83,108,138,151) but also in mouse models 
(unpublished results from our group), it is not unexpected that stimulation of p53 
expression has been described for some RR inhibitors (112,131) (Table 3). However, there 
is a surprisingly low number of reports on p53 activation by thiosemicarbazones and no 
correlation between p53 status and anticancer activity was found for several Dp44mT 
derivatives or Triapine (189,196). This led (at least in case of Dp44mT) to the suggestion 
that mouse double minute 2 homolog (MDM2)-mediated protein degradation could be 
responsible for p53-independent p21waf regulation (131). Nevertheless, Yu et al. identify 
three thiosemicarbazone derivatives (NSC319725 and NSC319726, both terminally 
substituted FTSC derivatives, as well as NSC328784, a selenosemicarbazone derivative of 
COTI-2) in the NCI60 screen database, which showed preferential anticancer activity in 
p53-mutant cell models harboring the R175 mutation (196). Subsequent analysis revealed 
that these effects are based on the restoration of a p53 “wild type-like confirmation” in an 
iron-sensitive manner (in case of NSC319726 addition of FeSO4 completely abrogated the 
activity) (196).  
Interestingly, there are also reports on the interaction of cyclin D1 with the mitochondrial 
regulation (145). Thus, knock-out of cyclin D1 leads to increased mitochondrial size and 
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activity. Accordingly, inactivation of the CDK/cyclin substrate Rb and overexpression of p21 
resulted in inhibition of the mitochondrial metabolism (145). Furthermore, there are 
several heme proteins such as cytochromes or nitric oxygenase, which are crucial for 
mitochondrial function (201). In line with this, there are some reports how 
thiosemicarbazones affect the mitochondria. On the one hand, induction of apoptosis via 
the intrinsic (mitochondria-mediated) pathway has been described for diverse 
representatives of this compound class (1,7,97,144,147,170,200). However, as 
thiosemicarbazones induce apoptosis usually only at quite high drug concentrations (far 
above the IC50 values), they can be considered rather as cytostatic agents which mainly 
execute their activity via cell cycle arrest. On the other hand, at least for Triapine and 
Dp44mT also a perturbation of the mitochondrial redox homeostasis was reported 
(133,134). Thus, treatment resulted in oxidation of mitochondrial Trx2 and, subsequently, 
the inability of the treated cells to maintain the redox state of Trx2-dependent proteins 
such as peroxiredoxin 3 (Prx3) (134) (Table 3). In line with these findings, Triapine 
treatment was distinctly more efficient in cells with Prx3 and Trx2 knockdown (134). 
However, in this study no signs of global redox stress in the cytosol of Triapine-treated 
cells were detected (134). Thus, for example several cytosolic redox proteins like Trx1, and 
Prx1, or endoplasmic Prx4 remained unchanged at clinically relevant concentrations (low 
µM range) (133). This preferential oxidation of mitochondrial Trx2 and Prx3 after Triapine 
treatment could be explained by an organelle-specific accumulation of the iron(III) 
complex of Triapine, as lipophilic cations can accumulate at several hundred-fold higher 
levels inside the mitochondria because of the large mitochondrial membrane potential 
(134). On the other hand, it is also possible that Triapine increases the mitochondrial 
peroxide (or other ROS) levels that may directly promote Prx3 oxidation. Also in case of 
Dp44mT (and to some extent DFO), interaction with the mitochondria was indicated by 
reports of treatment-induced upregulation of adenosine monophosphate-activated 
protein kinase (AMPK) a protein which is important for the restoration of the cellular 
energy levels (104) at low ATP levels, e.g. in response to mitochondrial dysfunction or 
stress (82). 
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Besides inhibition of cell cycle progression and (to some extent the induction of apoptotic 
cell death), more recently also induction of ER stress and autophagy have been described 
for several thiosemicarbazones (e.g. Triapine and it’s terminally dimethylated derivative 
PTSC (180), Dp44mT (111,125,158) as well as a combination of DpC with N,N,N´,N´-
tetrakis-[2-pyridylmethyl]-ethylenediamine (195)) in cancer cells. However, autophagy 
induction was also reported for two thiosemicarbazones, which are unlikely to form stable 
metal complexes (2-(acridin-9-ylmethylene))-N-phenylhydrazinecarbothioamide in breast 
cancer cells (33) and 4-nitrobenzaldehyde thiosemicarbazone in leishmania (162)), 
indicating that this mode of action is not primarily attributed to their interaction with 
cellular metal metabolism. 
 
Copper(II) complexes of thiosemicarbazones 
Due to the generally strong metal-binding properties of thiosemicarbazones, besides their 
interaction with iron(II/III) ions also complex formation with other biologically relevant 
metals has been repeatedly suggested (87,90). In this respect, especially copper 
complexation has been discussed in the mode of action for several thiosemicarbazones, as 
both -N-pyridyl- and salicylaldehyde-type thiosemicarbazones form mono-ligand 
copper(II) complexes with very high stabilities (43-45). In fact, thiosemicarbazones have 
typically a much stronger affinity towards copper(II) ions compared to iron ions and the 
stability of the formed copper(II) complexes e.g. for Triapine is so high that their 
decomposition at pH 7.4 even at 1 M concentration is negligible (≤ 1%) (43). In line, for 
Dp44mT a strong preference for copper complexation compared to iron(II) or zinc(II) was 
reported (53). In contrast to the trend observed for the iron complexes, in case of 
copper(II), N-terminal dimethylation of the thiosemicarbazone ligands had only minor 
effects on the complex stability (39). However, it has to be considered that intracellular 
iron is rather easily accessible via the labile iron pool, whereas under healthy conditions 
“available” copper cannot be found as most of the copper is protein-bound.  
During the last decades, multiple cell culture studies have been performed investigating 
the anticancer activity of preformed copper thiosemicarbazone complexes 
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(2,17,85,135,161). Here, generation of ROS based on the reduction of Cu(II) to Cu(I) by 
intracellular reducing agents is so far assumed to be the major mode of action underlying 
the anticancer activity of such copper(II) thiosemicarbazone complexes (2,17,85,135,161). 
However, our own studies indicated that this might not be a general rule, as for example in 
case of Triapine, the intracellular milieu seems not to be sufficient to allow significant 
redox cycling and ROS generation of the respective copper(II) complexes (100).  
With regard to metal-free ligands and their cellular interaction with copper, the available 
data are quite controversial. As already mentioned above, there are several reports stating 
that at IC50 concentrations no signs of global ROS formation (e.g. by using DCF-DA stains) 
were detectable when metal-free thiosemicarbazone ligands were used (100,115,134). 
Moreover, similarly to iron thiosemicarbazone complexes, so far no experimental proof of 
intracellular copper complex formation exists. Both aspects could be explained by a low-
level and organelle-specific formation of such complexes. Consequently, in case of 
Dp44mT (and its derivatives), for which an important role of copper has been proposed, 
Lovejoy et al. suggested that due to its “polyprotic nature” Dp44mT as well as its copper 
complex are specifically trapped in the acidic lysosomes (115). However, detailed solution 
equilibrium studies proving this hypothesis are still missing. This lysosomal accumulation 
subsequently leads to oxidative damage of the lysosomal membrane and induction of 
lysosomal cell death (62).  
In general, it can be summarized that intracellular complex formation of 
thiosemicarbazones with copper(II) ions is mainly discussed for terminally di-alkylated 
thiosemicarbazones like Dp44mT and DpC, which are characterized by cytotoxic activity in 
cell culture in the nanomolar range. These compounds also show a very strong synergistic 
activity with copper(II) salts, in contrast to thiosemicarbazones like Triapine with even 
antagonistic effects with copper(II) (83,101). As the stability of the copper(II) complexes, 
however, does not seem to be the crucial parameter, other factors like the 
thermodynamics and kinetics of the reduction process in the cellular environment are 
probably more important in this aspect. 
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Drug resistance - background  
Drug resistance is still one of the main reasons for the failure of anticancer therapies, 
especially at the late stage of the disease, when tumor cells have spread throughout the 
patient´s body (67). Even in case of novel targeted therapeutics such as tyrosine kinase 
inhibitors that were designed based on the increased understanding of the so called 
“cancer hallmarks” (67,68), clinical trials of the last 15 years proved that cancer cells can 
rapidly become resistant through multiple mechanisms (15,55,57,58,88,92,190). The 
challenges experienced with targeted therapeutics highlight the importance of research on 
traditional chemotherapeutic approaches. Given the complexity and heterogeneity of 
cancer, “dirty drugs” targeting multiple enzymes may avoid resistance mechanisms limiting 
the success of existing treatment schemes (48). Several chemotherapeutics have been 
shown to modulate more than a single molecular target or pathway, suggesting that such a 
promiscuous behavior may be key to long-term therapeutic efficiency (3,16). Also metal-
interacting drugs, including thiosemicarbazones hit multiple targets related to tumor 
growth, drug resistance and metastasis (“triad of death”, see (84)), which is why they are 
considered as prime examples of the success and promise of “polypharmacology”. As 
described above, the mechanisms of action of anticancer thiosemicarbazones are not 
entirely understood – and unfortunately even less is known about mechanisms of 
resistance against these drugs. 
 
In general, drug resistance can be classified into two types (72). On the one hand, tumor 
cells might prove unresponsive to therapy already at the first treatment (“intrinsic drug 
resistance”). On the other hand, drug-resistant tumors can arise following initial response 
to therapy (“acquired resistance”) (72). Several resistance mechanisms inhibit the delivery 
of drugs to their cellular target. Reduced delivery can be based on the tumor-specific 
microenvironment (e.g. poor vascularization of the malignant tissue) or cellular 
mechanisms spanning from enhanced drug efflux, reduced drug uptake, altered drug 
distribution to (especially in case of targeted therapeutics) target mutation/modification 
resulting in loss of binding and steric hindrance (Figure 6) (58,72,88,92). Even if the target 
is reached, tumor cells may still survive by the inactivation of programmed cell death 
execution pathways, enhanced damage repair (in case of DNA-damaging agents) or 
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upregulation of oncogenic by-pass mechanisms (in case of targeted drugs) (Figure 6) 
(58,72,88,92). In addition, activation of cell cycle checkpoints can contribute to survival 
during therapy. A frequently observed problem is the occurrence of multi-drug resistance 
(MDR), when cells become cross-resistant to multiple structurally and mechanistically 
unrelated drugs (57). The most prominent and best-understood MDR mechanism is the 
active drug export due to the overexpression of efflux pumps (ATP-binding cassette (ABC) 
transporters). This family of ATP-driven, membrane-spanning proteins is involved in the 
transmembrane transport of a vast array of potentially toxic molecules that include toxins, 
peptides, sugars, lipids, but also chemotherapeutics and diverse pharmaceutical agents 
(34,49,57,177). Cancer cells frequently hijack these physiological protection mechanisms 
to shield themselves from the toxic insult of therapy (72,160). In particular, anticancer 
drug resistance has been linked to the overexpression of P-glycoprotein (ABCB1), 
multidrug resistance-associated proteins 1 and 2 (MRP1/2, ABCC1/2) and the breast 
cancer resistance protein (BCRP, ABCG2) (176). 
 
Resistance against thiosemicarbazones 
As already pointed out above, results of clinical trials assessing the activity of Triapine, 
especially in solid tumors, were overall rather disappointing. One important aspect is the 
rapid excretion and, thus, very short plasma half-life of this thiosemicarbazone (<1 h in 
humans) (56,91,143,186). Given the cytostatic (rather than cytotoxic) activity of Triapine, 
one could hypothesize that the transient Triapine plasma levels are insufficient for efficient 
drug delivery and long-lasting RR inhibition in solid tumor nodules. Moreover, as 
mentioned above, cancer cells can adapt to treatment by transiently arresting proliferation 
through the activation of cell cycle checkpoints, until the drug levels are below 
pharmacologically active concentrations.  
In order to better understand the mechanisms leading to resistance to 
thiosemicarbazones, several representatives have been studied using in vitro models, 
typically based on cell lines cultured in the presence of increasing concentrations of the 
thiosemicarbazone. Early studies on a murine leukemia cell line selected for resistance 
against MAIQ suggested that Triapine is recognized and transported by ABCB1 and ABCC1 
(29,152) (interestingly, this cell line was later described to additionally overexpress 
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disulfide isomerase, a protein of the thioredoxin superfamily (30)). Similarly, screening of 
diverse compounds resulted in a number of other thiosemicarbazones, which were found 
to be substrates for ABCB1 (65,127), ABCG2 (38,73) or other (non-human) ABC 
transporters (13,18). Also the Triapine-resistant SW480 cell line developed in our lab 
showed massive overexpression of ABCB1 via activation of phosphokinase C (PKC) (127). 
However, in contrast to the above mentioned previous report (152), Triapine proved to be 
only a weak ABCB1 substrate in two human MDR models and ABCB1 inhibition did not re-
sensitize the Triapine-resistant SW480 cells to thiosemicarbazone treatment (127). In 
contrast, as already described above, the resistance in Triapine-resistant SW480 cells was 
based on the hyper-activation of the cAMP-signaling pathway (126). Interestingly, some 
reports suggest that common ABCB1 (and ABCC1) haplotypes may influence sensitivity of 
patients to Triapine treatment (26,179). Thus, patients with wild-type ABCB1 exhibited 
higher plasma levels along with an increased occurrence of dose-limiting toxicities (26), 
while the C3435T variant was associated with prolonged overall survival (179). 
Unfortunately, since tumoral ABCB1 levels were not assessed, it remains unclear whether 
tumor-associated ABCB1 had impact on the response in these clinical trials.  
 
Especially with regard to drug resistance and the impact of ABC transporters, strong 
structure-activity relationships were observed for several thiosemicarbazones indicating 
that already small modifications of the structure may result in distinct changes of the drug 
resistance profile. For example, methylation of the pyridine- and terminal amino-groups of 
Triapine resulted in increased activity against Triapine-resistant SW480 cells (101). In 
addition, N-terminal dimethylation of Triapine derivatives led to recognition by ABCC1 as 
well as ABCG2 and (probably glutathione-associated) efflux from resistant cancer cells (73), 
resulting in distinct differences in the resistance pattern of the derivatives being active at 
nanomolar concentrations compared to other thiosemicarbazones. Interestingly, structural 
modification of certain isatin-derivatives led to an increased, rather than decreased 
activity in ABCB1-overexpressing cell lines (80,118). This phenomenon is called “collateral 
sensitivity” and will be discussed in more detail in the next section. 
As already indicated in the chapter above, drug resistance is frequently associated with 
changed intracellular drug levels. Besides enhanced efflux (most prominently via ABC 
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transporters) also reduced drug uptake is frequently observed (72). For example, in case of 
the clinically approved drugs cisplatin and carboplatin, the copper transporter 1 (Ctr1) 
seems to be responsible for cellular accumulation and consequently, cells with acquired 
drug resistance were characterized by Ctr1 downregulation. Notably, also the isatin-β-
thiosemicarbazone NSC73306 has been identified as a Ctr1 substrate (and its uptake was 
blocked by cisplatin coincubation) (50). Moreover, in case of Dp44mT and other 
derivatives of the DpT class (but not Triapine or most derivatives of the BpT or ApT series), 
uptake via a carrier-/receptor-mediated mechanism was suggested (125). It is still a matter 
of debate (124,193), whether the (rather weak) albumin binding of Dp44mT is involved in 
this cellular uptake mechanism. Nevertheless, it is interesting that in several cell lines co-
incubation of Dp44mT with human serum albumin resulted in enhanced cellular uptake of 
the thiosemicarbazone (124). A possible explanation is the (direct) interaction of albumin 
with Ctr1 (93,168), which could point towards a role of Ctr1 also in the uptake of Dp44mT. 
However, as knockdown of Ctr1 did only marginally affect the sensitivity of KB cells to 
NSC73306 (50), the role of Ctr1 in resistance to thiosemicarbazones is unclear and needs 
further investigation. 
Besides the changed intracellular drug levels (and the above-mentioned impact of RNA 
polymerase mutations in case of antiviral activity of some thiosemicarbazones), the 
cellular mechanisms of thiosemicarbazones resistance have not been investigated in 
depth. Considering the central role of RR in the anticancer activity of thiosemicarbazones, 
it is worth-mentioning that although overexpression of hRRM2 is a common resistance 
mechanism for clinically approved RR inhibitors like hydroxyurea or gemcitabine, multiple 
RR-overexpressing cell lines (e.g. HU-7-S7, L1210/ED1, L1210/ED2, KB-HU or KB-GEM) 
displayed only a trend towards drug resistance against MAIQ or diverse Triapine 
derivatives (19,28,202). In some cases, even enhanced sensitivity of these cell lines to 
thiosemicarbazone treatment was observed (202). Overall, this indicates that the RR 
expression levels do not have a central role in the resistance against thiosemicarbazones.  
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Thiosemicarbazones with MDR-selective activity  
As already mentioned above, certain thiosemicarbazones (mainly isatin derivatives 
including NSC73306 but also Dp44mT) show increased, rather than decreased toxicity 
against ABCB1-expressing MDR cells (51,65,86,118,139,164,165,175,176,182,194). This 
“MDR-selective” toxicity is shared by several other compounds which are able to chelate 
metal ions including some 8-HQ or phen derivatives (51,70,74,80,182). This paradoxical 
hypersensitivity (collateral sensitivity) of multidrug-resistant cells suggests that, in addition 
to limiting the efficacy of chemotherapy, ABCB1 should be considered as a “double-edged 
sword”, which may be turned against cancer cells. However, as for many aspects of the 
thiosemicarbazone compound class, the exact mode of MDR-selective toxicity is not 
understood.  
Following the discovery of the lysosomal accumulation of the redox-active copper complex 
of Dp44mT (115), it was postulated that the increased toxicity against MDR cells is due to 
the function of lysosomal ABCB1 (86). Whereas ABCB1 usually resides in the plasma 
membrane, glucose modulation was found to specifically increase the lysosomal 
accumulation of ABCB1 together with an increase of the sensitivity of MDR cells toward 
Dp44mT (164). A similar mechanism was postulated for related ligands including Ap44mT 
(the acetylpyridine analogue of PTSC) and DpC as well as their zinc complexes, following 
trans-metalation to the respective copper complexes (174,194). The functionality of 
intracellular (lysosomal) ABCB1 could be demonstrated by increased lysosomotropic drug 
sequestration (194), which led to a model suggesting that in MDR cells Dp44mT is targeted 
to the lysosomes by ABCB1 (86). Congruently with this hypothesis, Dp44mT did not prove 
to be selectively toxic to MDR cells expressing ABCB1 in the plasma membrane, suggesting 
that sensitivity against Dp44mT is restricted to MDR cells with lysosomal ABCB1 (51). At 
present, the clinical relevance of lysosomal ABCB1 remains to be verified. Given the 
complexity of the mode of action of Dp44mT (Table 3), additional molecular alterations 
restricted to particular cell models may be necessary for the paradoxical increase of its 
toxicity in MDR cells. 
Several MDR-selective compounds with chelating moieties (including isatin-β-
thiosemicarbazones such as NSC73306) were identified possessing increased toxicity 
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against MDR cells expressing ABCB1 solely in the plasma membrane (51). These were 
identified by a pharmacogenomic approach, correlating gene expression and drug activity 
patterns recorded against 60 cancer cell lines of different tissue origin (NCI 60 Screen) 
(118,153,169,176). In contrast to serendipitously found MDR-targeting compounds whose 
preferential toxicity is often limited to specific cells, the MDR-selective toxicity of 
compounds identified based on the pharmacogenomic approach is mediated by surface-
expressed ABCB1 (51,175,182). These reports support the notion that ABCB1, which is 
considered to be an universal marker of drug resistance, should be interpreted as a trait 
that can be targeted by new drugs (64,65,175). 
Structure-activity relationships predicting chemical features responsible for susceptibility 
to transport (Triapine and Dp44mT) or ABCB1-mediated toxicity (NSC73306) are not 
entirely understood (139). While Dp44mT is relatively similar to Triapine, 
thiosemicarbazones identified by the correlative approach are isatin-β-
thiosemicarbazones, which chelate metal ions via an (O,N,S) donor atom set and have a 
different substitution pattern at the terminal nitrogen atom (64,65,182). For isatin-β-
thiosemicarbazones, a pharmacophore model was suggested (64,65,176), identifying 
chemical features that fine-tune selective toxicity towards ABCB1-expressing cells, as 
summarized in Figure 7. It has to be noted that the model shown in Figure 7 could not be 
validated in a more extended library of thiosemicarbazones (139), suggesting that the 
identified descriptors are unique for this compound class. The role of the ligands’ redox 
activity or complex stability with biologically relevant metal ions in MDR-selective toxicity 
is not known, as stability data for iron complexes of isatin-β-thiosemicarbazones are not 
available. However, based on their coordination mode, a decreased iron-binding ability 
(especially diminished for iron(II)) could be expected for these ligands, as compared to the 
-N-pyridyl thiosemicarbazones. Although cells become more sensitive with the 
expression of ABCB1 (but not ABCG2 (191)), the mechanism of toxicity does not rely on the 
direct interaction with the transporter (118).  
 
Taken together, the mechanisms responsible for MDR-selective toxicity are unknown. 
Chelation seems to be a necessary, although not sufficient, prerequisite but the nature of 
the metal complexes formed and the elicited cellular alterations remain elusive (176). 
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Although the exact mechanism remains to be discovered, the MDR-selective toxicity of 
thiosemicarbazones represents a robust modality for targeting MDR cancer and might 
represent a promising modality for the treatment of late stage patients after failure of 
therapy due to ABCB1 expression. 
 
Conclusions  
In this review, we highlight and summarize the current knowledge on anticancer 
thiosemicarbazones with respect to their physico-chemical data with iron, interaction with 
the cellular iron homeostasis and resistance development. By this we wanted to 
emphasize that thiosemicarbazones are generally not “simple” chelators removing cellular 
iron but have to be considered as iron/metal-interacting drugs with a multi-facetted mode 
of action.  
For the most prominent representative Triapine, despite multiple phase I/II trials, clinical 
approval seems to be difficult. However, over the last few decades a great amount of 
additional knowledge has been gained on the biological activity of thiosemicarbazones in 
cell culture and in vivo. At least partially, these data have already been used to generate 
novel, improved compounds (two of them currently in clinical phase I trials), which 
hopefully will overcome the drawbacks of Triapine finally resulting in a thiosemicarbazone 
approved for cancer treatment. 
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311  2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazine; 
3-AP  Triapine, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone;  
5-HP  5-hydroxyl-2-formylpyridine thiosemicarbazone;  
8-HQ  8-hydroxyquinoline;  
ABC  ATP-binding cassette;  
ABCB1 P-glycoprotein;  
ABCC1 multidrug resistance associated protein 1;  
ABCC2 multidrug resistance associated protein 1;  
ABCG2 breast cancer resistance protein;  
AMPK  adenosine monophosphate-activated protein kinase;  
Ap44mT 2-acetylpyridine 4,4-dimethyl-3-thiosemicarbazone;  
cAMP  cyclic adenosine monophosphate;  
CDK  cyclin-dependent kinase;  
DCF-DA 2',7'-dichlorodihydrofluorescein diacetate;  
DFO  desferrioxamine;  
dNTPs  desoxyribonucleoside diphosphates;  
Dp44mT di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone;  
ε’  formal redox potential;  
EPR  electron paramagnetic resonance;  
FTSC  2-formylpyridine thiosemicarbazone;  
hRRM1/2 subunits of human RR protein;  
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MAIQ  4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone;  
MDR  multidrug resistance;  
NHE  normal hydrogen electrode;  
NDRG1/2 N-myc downstream-regulated gene 1 or 2;  
PDE4D cAMP-specific 3',5'-cyclic phosphodiesterase 4D;  
PDI  protein disulfide isomerases;  
Phen  1,10-phenanthroline;  
PIH  pyridoxal isonicotinoyl hydrazine;  
PKA  protein kinase A;  
PTSC  N,N-dimethyl-2-formylpyridine thiosemicarbazone;  
Prx  peroxiredoxin;  
pM  negative logarithm of the equilibrium concentrations of the unbound metal 
ion (pM = –log[M])  
ROS  reactive oxygen species;  
RR  ribonucleotide reductase;  
STAT3 signal transducer and activator of transcription 3;  
STSC  salicylaldehyde thiosemicarbazone;  
Triapine 3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 
TSC24  N,N-dimethyl-2-(quinolin-2-ylmethylene)hydrazinecarbothioamide; 
Trx  thioredoxin. 
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Table 1. Cumulative stability constants (log β) of iron(III) and iron(II) complexes of DFO and 
selected thiosemicarbazones. 
logβ DFO Triapine FTSC Dp44mT STSC 
Fe(III)L 30.4 a n. r. n. r. n. r. n. r. 
Fe(II)L 10 b n. r. n. r. n. r. n. r. 
Fe(III)L2 n. r. 26.25 c 25.36 c 23.6 d 34.02 e 
Fe(II)L2 n. r. 22.55 c 22.31 c 21.2 d 24.73 e 
a Ref (69); b Ref (172); c Data obtained in 30% (w/w) DMSO/H2O (44); d Values 
estimated from the conditional constants obtained at pH 5: Fe(III)L2: 12.67 and 
Fe(II)L2: 10.25 (52); e Data obtained in 30% (w/w) DMSO/H2O (45). n. r. = not 
relevant for the given ligand system. 
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Table 2. Physico-chemical properties of selected iron(III) complexes formed with ligands 
containing different donor atoms  
Ligand  coordination mode pMa ’ (mV) vs. NHE 
Deferiprone  3×(O,O‒) 20.5 (76); 19.4 (77) ‒620 (123) 
Deferasirox  2×(O‒,N,O‒) 22.5 (75) ‒600 (76) 
DFO  (O,O‒,O,O‒,O,O‒) 26.6 (172) ‒482 (172) 
8-HQ  3×(O‒,N) 20.6 (76) ‒150 (76) 
Triapine  2×(N,N,S‒) 15.7 (44) +70 (44), +40 (150) 
DpC  2×(N,N,S‒) not available +94 (150) 
Dp44mT  2×(N,N,S‒) ~14(52)b +113 (150), +166 (155) 
PIH 2×(O‒,N,O‒) 22.9 (156) (185)c +130 (75) 
Phen 3×(N,N) unstable +1140 (113) 
Transferrin (COO‒,O‒,N,O‒
,CO32‒) 
20.3(130) not available 
a pM values (pM = –log[Fe(III)] at cFe(III) = 1 µM; cL = 10 µM; pH = 7.4) and formal (’) 
potentials vs. NHE of the iron(III)/iron(II) complexes (pH = 7.4). bpM is estimated on the 
basis of the conditional constants reported at pH 5 in reference (52) and transferred to pH 
7.4 with the use of the protonation constants of the ligand and the hydrolysis constants of 
iron(III) (22). c pM is calculated from equilibrium constants reported in (156,185).  
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Table 3. Overview on biological thiosemicarbazone targets described.  
Target Drug Level of evidence (used method) 
Hemoglobin Triapine In humans (methemoglobinemia) (94,107) 
 Dp44mT In mice and isolated human red blood cells (methemoglobin 
formation) (150) 
RR Triapine In humans (depletion of dNTP pools in leukemia cells) (56,109) 
Cell culture (whole cell EPR, inhibition of dCTP production) 
(6,99) 
Cell-free enzyme inhibition (EPR) (167,202) 
 Dp44mT, 
Dp4eT 
Cell culture (whole cell EPR) (198) 
 IQ-1 Cell-free enzyme inhibition (EPR) (178)
DNA Triapine Cell culture (H2AX phosphorylation) (83,108) 
In mice (immunofluorescence stain, H2AX phosphorylation in 
subcutaneous tumors, unpublished results) 
 Dp44mT Cell culture (H2AX phosphorylation) (83,151) 
STAT3 DpC, 
Dp44mT 
In mice (immunofluorescence stain of subcutaneous tumors) 
(119) 
Cell culture (Western blot, DNA-binding activity) (119,187) 
NDRG1/2/3 Dp44mT In mice (immunofluorescence stain of subcutaneous tumors) 
(110) 
Cell culture (Western blot) (110,120,187) 
 DpC Cell culture (Western blot) (97) 
Cyclin A Triapine Cell culture (Western blot) (23) 
 TSC24 Cell culture (Western blot) (7) 
Cyclin D Triapine Cell culture (Western blot) (23) 
 Dp44mT Cell culture (Western blot) (110,111) 
 DpC Cell culture (Western blot) (97)
CDK2/4 Triapine Cell culture (Western blot) (23) 
 Bp4eT, Cell culture (CDK2 activity by immunoprecipitation) (35) 
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Dp44mT 
PDE4D Triapine Cell culture (loss in resistant cell lines) (126) 
P53 NSC319725, 
NSC319726, 
NSC328784 
Cell culture (restoring p53-wt confirmation) (196) 
P21 DpC Cell culture (Western blot) (97,131)
 TSC24 Cell culture (Western blot) (7) 
Trx2 Triapine Cell culture (Western blot) (134) 
Prx3 Triapine, 
Dp44mT 
Cell culture (Western blot) (133)
AMPK Dp44mT Cell culture (Western blot) (104) 
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Figure 1: Chemical structures of clinically investigated or approved thiosemicarbazones 
with highlighted donor atoms. (To see this illustration in color, the reader is referred to the 
online version of this article at www.liebertpub.com/ars). 
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Figure 2: Chemical structures of the α-N-heterocyclic thiosemicarbazones FTSC and 
Dp44mT with N,N,S donor sets, STSC with O,N,S donor atoms, the iron chelators 1,10-
phenanthroline (phen), 8-hydroxyquinoline (8-HQ) and pyridoxal isonicotinoyl hydrazine 
(PIH) as well as the clinically approved iron(III) chelators desferrioxamine (DFO), 
deferiprone and deferasirox. (To see this illustration in color, the reader is referred to the 
online version of this article at www.liebertpub.com/ars). 
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Figure 3: General (de)protonation steps of an α-N-pyridyl thiosemicarbazone ligand [H2L]+ 
shown for FTSC. 
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Figure 4. Distribution of iron(II) and iron(III) between two different types of 
thiosemicarbazone complexes in a hypothetic metal/FTSC/STSC (1:2:2) ternary system at 
pH 7.4 (cFe = 1 mM) calculated based on the stability constants (43,44). The STSC ligands 
with the harder (O,N,S,) donor set have a much higher affinity for Fe(III) ions, whereas the 
(N,N,S) donor set of FTSC prefers iron(II) ions.   
 
  
D
ow
nl
oa
de
d 
by
 K
in
gs
 C
ol
le
ge
 L
on
do
n-
jou
rna
l S
ect
ion
 fr
om
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 01
/16
/18
. F
or 
pe
rso
na
l u
se 
on
ly.
 
Page 61 of 63 
 
 
 
61 
An
tio
xid
an
ts
 a
nd
 R
ed
ox
 S
ig
na
lin
g 
An
tic
an
ce
r t
hi
os
em
ica
rb
az
on
es
: c
he
m
ica
l p
ro
pe
rt
ie
s, 
in
te
ra
ct
io
n 
w
ith
 ir
on
 m
et
ab
ol
ism
, a
nd
 re
sis
ta
nc
e 
de
ve
lo
pm
en
t (
DO
I: 
10
.1
08
9/
ar
s.2
01
7.
74
87
) 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
 
Figure 5. Possible interaction of the iron complex of a terminally unsubstituted 
thiosemicarbazone and the porphyrin system of hemoglobin (drawn according to 
reference (11)). 
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Figure 6. Cellular mechanisms of resistance. The development of MDR is a multifactorial 
process, and the MDR phenotype implies a number of cellular changes. Resistance can 
emerge as a result of genetic changes. Here, targets can be overexpressed or structurally 
modified in a manner that drug binding is reduced, or sterically hindered. Adaption can 
also rely on increased repair of the damage (e.g. DNA adducts). Especially in case of 
targeted drugs, alternative signaling pathways can be modified, in order to overcome the 
dependence on the drug target. Altered cellular metabolism can lead to the inactivation or 
decreased activation of the cytotoxic agent, accompanied by changes in metabolic 
enzymes, as well as by changes in cellular energy metabolism, metal- and redox 
homeostasis. Furthermore, the cellular response to drugs can also be altered by lowering 
intracellular drug concentrations as a result of the reduced uptake or the enhanced efflux 
of compounds. Usually, efflux is based on energy-dependent transport mediated by ATP-
binding-cassette (ABC) proteins, such as ABCB1. In addition, altered intracellular drug 
distribution has been frequently described for drug-resistant cells. (To see this illustration 
in color, the reader is referred to the online version of this article at 
www.liebertpub.com/ars). 
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Figure 7: SAR / pharmacophore model of isatin-β-thiosemicarbazone, based on 
(62,63,167). The thiosemicarbazone scaffold and a bulky or aromatic moiety at N4 are 
required for MDR-selective toxicity. Substitutions of the aromatic moiety at position 4’ 
were found to be optimal, while ortho (2’) and meta (3’) substitutions were not beneficial 
(167). The isatin moiety – or at least the lactam – seems to be necessary for selective 
activity. An extension of the aromatic ring system disrupts activity, while substitution at 
the 5th position might be tolerated in case of halogens or a nitro-group, but not in case of 
a sulfonate, which might be explained by a reduced cell permeability of the resulting 
negatively charged molecule (63). 
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